Literature DB >> 19791836

Polymorphism of the micro-opioid receptor gene (OPRM1 118A>G) affects fentanyl-induced analgesia during anesthesia and recovery.

Wei Dong Wu1, Yi Wang, Yong Ming Fang, Hai Yan Zhou.   

Abstract

BACKGROUND: There is much variation in the response of both individuals and different ethnic populations to opioids, with genetic differences being responsible for interindividual variation. The micro-opioid receptor single nucleotide polymorphism (rs number 1799971) at nucleotide position 118 (OPRM1 118A>G) affects the analgesic response to opioids.
OBJECTIVE: This study aimed to investigate the association between the OPRM1 118A>G polymorphism and the effects of fentanyl-induced analgesia, respiratory depression, and anesthetic recovery responses in a population of Han Chinese patients. STUDY
DESIGN: The study was a case series in a hospital setting, with 1 year of study and 1 year of follow-up. A total of 189 patients (92 males and 97 females; American Society of Anesthesiologists Physical Status I or II, Glasgow Coma Scale = 15) who were scheduled for laparoscopic abdominal surgery received intravenous midazolam (Versed) 0.08-0.01 mg/kg and fentanyl (Duragesic) 5.0 microg/kg. The main outcome measure was the degree of postoperative pain, as assessed using the Visual Analog Scale (VAS). VAS scores were recorded 5, 15, 30, 45, and 60 minutes after a fentanyl bolus injection in the post-anesthesia care unit (PACU). The minute expiratory volume, end-tidal carbon dioxide concentration (EtCO(2)) and respiratory rate (RR) were measured continuously. The incidence of fentanyl-induced respiratory depression (RR <8/min and EtCO(2) >45 mmHg) was recorded at its appearance and treated with respiratory assistance. Blood gas analysis was done 15, 30, 45, and 60 minutes after extubation. These parameters were correlated with genotyping results of genomic DNA extracted from whole blood.
RESULTS: Patients with the OPRM1 118 AG or GG genotypes had significantly higher VAS pain scores 15 and 30 minutes after a fentanyl bolus injection in the PACU than AA genotype patients (p < 0.05). A small but statistically significant difference was observed between the 118 AA and 118 AG/GG genotypes with regard to the carbon dioxide arterial pressure (PaCO(2)) at 15 and 30 minutes from the fentanyl bolus injection after extubation (p < 0.05); however, no clinically significant difference in the frequency of respiratory depression was seen. Homozygous 118 GG genotype patients had a significantly shorter time to awakening (p = 0.018) and extubation (p = 0.024) than patients with the 118 AA genotype. When the 118 GG and 118 AG genotypes were combined for analysis, a significantly shorter time to awakening (p = 0.011) and extubation (p = 0.010), compared with the 118 AA genotype, was also seen.
CONCLUSION: The OPRM1 118A>G polymorphism lessens the analgesic response to fentanyl and the time to awakening and extubation but has no clinically significant effect on the incidence of respiratory depression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19791836     DOI: 10.1007/bf03256337

Source DB:  PubMed          Journal:  Mol Diagn Ther        ISSN: 1177-1062            Impact factor:   4.074


  29 in total

1.  Genetics of two mu opioid receptor gene (OPRM1) exon I polymorphisms: population studies, and allele frequencies in alcohol- and drug-dependent subjects.

Authors:  J Gelernter; H Kranzler; J Cubells
Journal:  Mol Psychiatry       Date:  1999-09       Impact factor: 15.992

Review 2.  Functional consequences of polymorphism of xenobiotic metabolising enzymes.

Authors:  M Ingelman-Sundberg
Journal:  Toxicol Lett       Date:  1998-12-28       Impact factor: 4.372

3.  Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G.

Authors:  Ying Zhang; Danxin Wang; Andrew D Johnson; Audrey C Papp; Wolfgang Sadée
Journal:  J Biol Chem       Date:  2005-07-26       Impact factor: 5.157

4.  A common human micro-opioid receptor genetic variant diminishes the receptor signaling efficacy in brain regions processing the sensory information of pain.

Authors:  Bruno Georg Oertel; Mattias Kettner; Klaus Scholich; Christoph Renné; Bianca Roskam; Gerd Geisslinger; Peter Harald Schmidt; Jörn Lötsch
Journal:  J Biol Chem       Date:  2008-12-30       Impact factor: 5.157

5.  Association of mu-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty.

Authors:  W-Y Chou; L-C Yang; H-F Lu; J-Y Ko; C-H Wang; S-H Lin; T-H Lee; A Concejero; C-J Hsu
Journal:  Acta Anaesthesiol Scand       Date:  2006-08       Impact factor: 2.105

Review 6.  Overview of enzymes of drug metabolism.

Authors:  U A Meyer
Journal:  J Pharmacokinet Biopharm       Date:  1996-10

7.  The A118G single nucleotide polymorphism of the mu-opioid receptor gene (OPRM1) is associated with pressure pain sensitivity in humans.

Authors:  Roger B Fillingim; Lee Kaplan; Roland Staud; Timothy J Ness; Toni L Glover; Claudia M Campbell; Jeffrey S Mogil; Margaret R Wallace
Journal:  J Pain       Date:  2005-03       Impact factor: 5.820

8.  mu opiate receptor: cDNA cloning and expression.

Authors:  J B Wang; Y Imai; C M Eppler; P Gregor; C E Spivak; G R Uhl
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-01       Impact factor: 11.205

9.  Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction.

Authors:  C Bond; K S LaForge; M Tian; D Melia; S Zhang; L Borg; J Gong; J Schluger; J A Strong; S M Leal; J A Tischfield; M J Kreek; L Yu
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

10.  The single nucleotide polymorphism A118G alters functional properties of the human mu opioid receptor.

Authors:  Thomas Kroslak; K Steven Laforge; Robert J Gianotti; Ann Ho; David A Nielsen; Mary Jeanne Kreek
Journal:  J Neurochem       Date:  2007-10       Impact factor: 5.372

View more
  16 in total

Review 1.  Pharmacogenetics of OPRM1.

Authors:  Richard C Crist; Wade H Berrettini
Journal:  Pharmacol Biochem Behav       Date:  2013-11-05       Impact factor: 3.533

2.  Differences in Clinical Pain and Experimental Pain Sensitivity Between Asian Americans and Whites With Knee Osteoarthritis.

Authors:  Hyochol Ahn; Michael Weaver; Debra E Lyon; Junglyun Kim; Eunyoung Choi; Roland Staud; Roger B Fillingim
Journal:  Clin J Pain       Date:  2017-02       Impact factor: 3.442

Review 3.  Genetic basis of pain variability: recent advances.

Authors:  Erin E Young; William R Lariviere; Inna Belfer
Journal:  J Med Genet       Date:  2011-11-05       Impact factor: 6.318

Review 4.  Pharmacogenetics of Methadone Response.

Authors:  Francina Fonseca; Marta Torrens
Journal:  Mol Diagn Ther       Date:  2018-02       Impact factor: 4.074

5.  Response to methadone maintenance treatment is associated with the MYOCD and GRM6 genes.

Authors:  Francina Fonseca; Mònica Gratacòs; Geòrgia Escaramís; Rafael De Cid; Rocío Martín-Santos; Emilio Fernández-Espejo; Xavier Estivill; Marta Torrens
Journal:  Mol Diagn Ther       Date:  2010-06-01       Impact factor: 4.074

6.  Aversive and reinforcing opioid effects: a pharmacogenomic twin study.

Authors:  Martin S Angst; Laura C Lazzeroni; Nicholas G Phillips; David R Drover; Martha Tingle; Amrita Ray; Gary E Swan; J David Clark
Journal:  Anesthesiology       Date:  2012-07       Impact factor: 7.892

Review 7.  Biologic mechanisms of oral cancer pain and implications for clinical therapy.

Authors:  C T Viet; B L Schmidt
Journal:  J Dent Res       Date:  2011-10-04       Impact factor: 6.116

Review 8.  Pharmacokinetics of non-intravenous formulations of fentanyl.

Authors:  Jörn Lötsch; Carmen Walter; Michael J Parnham; Bruno G Oertel; Gerd Geisslinger
Journal:  Clin Pharmacokinet       Date:  2013-01       Impact factor: 6.447

9.  Pain management with morphine: variation in analgesic response secondary to genetic polymorphisms.

Authors:  Shailendra Kapoor
Journal:  Ther Clin Risk Manag       Date:  2012-05-21       Impact factor: 2.423

10.  Consequences of the 118A>G polymorphism in the OPRM1 gene: translation from bench to bedside?

Authors:  Elisa Mura; Stefano Govoni; Marco Racchi; Valeria Carossa; Guglielmina Nadia Ranzani; Massimo Allegri; Ron Hn van Schaik
Journal:  J Pain Res       Date:  2013-05-01       Impact factor: 3.133

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.